Does SANDOSTATIN LAR Cause Second primary malignancy? 11 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Second primary malignancy have been filed in association with SANDOSTATIN LAR. This represents 2.8% of all adverse event reports for SANDOSTATIN LAR.
11
Reports of Second primary malignancy with SANDOSTATIN LAR
2.8%
of all SANDOSTATIN LAR reports
4
Deaths
8
Hospitalizations
How Dangerous Is Second primary malignancy From SANDOSTATIN LAR?
Of the 11 reports, 4 (36.4%) resulted in death, 8 (72.7%) required hospitalization, and 1 (9.1%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SANDOSTATIN LAR. However, 11 reports have been filed with the FAERS database.
What Other Side Effects Does SANDOSTATIN LAR Cause?
Death (117)
Diarrhoea (49)
Malaise (49)
Asthenia (45)
Malignant neoplasm progression (45)
Nausea (37)
Weight decreased (37)
Fatigue (36)
Pain (34)
Vomiting (31)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which SANDOSTATIN LAR Alternatives Have Lower Second primary malignancy Risk?
SANDOSTATIN LAR vs SANDOZ FENTANYL SYSTEM
SANDOSTATIN LAR vs SAPROPTERIN
SANDOSTATIN LAR vs SAQUINAVIR
SANDOSTATIN LAR vs SARECYCLINE
SANDOSTATIN LAR vs SARGRAMOSTIM